ZappRX, the app that aims to make it easier to manage specialty drug prescriptions, has pulled in $25 million in Series B funding led by Qiming US, the Chinese venture outfit’s stateside health care fund. GV (formerly Google Ventures) and GlaxoSmithKline’s funding arm SR One were also in the round and Qiming US’s Mark McDade will now join the board. ZappRx solves a unique… Read More on Tech Crunch